Gilead Sciences (GILD) 103.06 $GILD Midday Glan
Post# of 64200
Posted On: 03/04/2015 6:18:52 PM
Gilead Sciences (GILD) 103.06 $GILD
Midday Glance: Biotechnology companies
AP - Wed Mar 04, 12:16PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
GILD: 103.06 (+0.27), AMGN: 159.19 (+0.63), CELG: 119.57 (+1.10)
Biotech Stock Roundup: Orexigen Soars on Contrave Data, Amgen Scores in Study - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 04, 10:35AM CST
Orexigen (OREX) soars on news regrading obesity drug, Contrave. Amgen's (AMGN) multiple myeloma drug, Kyprolis, is better than Velcade in a head-to-head study.
OREX: 8.49 (+0.85), VRTX: 120.05 (-3.47), ISIS: 70.16 (+1.50), GILD: 103.06 (+0.27), AMGN: 159.19 (+0.63), ARNA: 4.32 (+0.28), CELG: 119.57 (+1.10)
Early Glance: Biotechnology companies
AP - Wed Mar 04, 9:36AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
GILD: 103.06 (+0.27), AMGN: 159.19 (+0.63), CELG: 119.57 (+1.10)
CVS Health Wins Over Analysts As Significant Growth Expected In The Next 5 Years
Equity Watch - at Seeking Alpha - Wed Mar 04, 8:17AM CST
GILD: 103.06 (+0.27), CVS: 103.08 (-0.37)
Pioneer Fundamental Growth Fund: Why Is It Revving Up?
at Investor's Business Daily - Tue Mar 03, 5:50PM CST
Stock mutual fund managers Andrew Acheson and Paul Cloonan have been kicking it into a higher gear at Pioneer Fundamental Growth Fund. The 16.61% average annual return of their $2.4 billion fund ranked in the top 27% of its large-cap growth rivals...
SBUX: 93.06 (-0.94), ESRX: 84.83 (+0.48), LNKD: 265.23 (-0.31), GILD: 103.06 (+0.27), ABBV: 60.27 (+0.65), AAPL: 128.54 (-0.82), CELG: 119.57 (+1.10)
Final Glance: Biotechnology companies
AP - Tue Mar 03, 5:05PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 103.06 (+0.27), AMGN: 159.19 (+0.63), CELG: 119.57 (+1.10)
Amgen: The Best Biotech Stock You Don't Own
Dan Strack - at Seeking Alpha - Tue Mar 03, 4:04PM CST
BIIB: 414.13 (+1.34), GILD: 103.06 (+0.27), PFE: 34.64 (+0.08), MRK: 57.88 (-0.46), AMGN: 159.19 (+0.63), ABBV: 60.27 (+0.65), GSK: 47.82 (+0.11), BMY: 65.67 (+3.75), HSP: 87.95 (+0.24), NVS: 99.04 (-0.02), CELG: 119.57 (+1.10)
Stock Markets Take a Breather After Monday's Record Run
at The Street - Tue Mar 03, 3:11PM CST
Stocks took a break from smashing records and hitting multi-year highs on Tuesday.
BCS: 16.03 (+0.37), PSX: 77.96 (-0.13), F: 16.03 (-0.14), DKS: 55.98 (-0.02), PFE: 34.64 (+0.08), C: 53.67 (-0.06), MYL: 55.60 (+0.16), BBY: 39.79 (+0.61), COP: 64.25 (-0.53), LL: 35.64 (-5.14), XLV: 72.58 (+0.35), CELG: 119.57 (+1.10), AZO: 652.48 (+0.58), TOT: 52.82 (-0.27), GILD: 103.06 (+0.27), TGT: 77.72 (-0.28), LEAF: 49.91 (-0.32), GM: 37.57 (-0.23), BP: 41.53 (-0.21), XLE: 78.65 (-0.11), BABA: 85.49 (+3.91)
Gilead Sciences' (GILD) Management Presents at Cowen & Company 35th Annual Health Care Conference (Transcript)
SA Transcripts - at Seeking Alpha - Tue Mar 03, 3:03PM CST
GILD: 103.06 (+0.27)
Stocks Recover From Lows After Crude Oil Jumps Over $50
at The Street - Tue Mar 03, 2:22PM CST
Stocks move off session lows by mid-afternoon Tuesday, buoyed by a rally in oil prices.
BCS: 16.03 (+0.37), F: 16.03 (-0.14), GE: 25.66 (-0.20), DKS: 55.98 (-0.02), PFE: 34.64 (+0.08), C: 53.67 (-0.06), MYL: 55.60 (+0.16), BBY: 39.79 (+0.61), LL: 35.64 (-5.14), XLV: 72.58 (+0.35), CELG: 119.57 (+1.10), AZO: 652.48 (+0.58), GILD: 103.06 (+0.27), GM: 37.57 (-0.23), LEAF: 49.91 (-0.32), BABA: 85.49 (+3.91)
Nasdaq Hits 5000: 3 Choices to Ride the Upswing - Analyst Blog
Swarup Gupta - Zacks Investment Research - Tue Mar 03, 10:36AM CST
Echoes of the dot-com boom could be heard yesterday after the Nasdaq closed above 5,000 for the first time in 15 years.
AMZN: 382.72 (-1.89), BIIB: 414.13 (+1.34), FB: 80.89 (+1.29), AMGN: 159.19 (+0.63), H: 60.77 (-0.49), INTC: 34.12 (+0.02), PCLN: 1,225.67 (-16.36), CELG: 119.57 (+1.10), SBUX: 93.06 (-0.94), GILD: 103.06 (+0.27), MSFT: 43.06 (-0.22), AAPL: 128.54 (-0.82), CSCO: 29.33 (-0.21), ONNN: 13.02 (+0.15)
Stocks Slip From Highs; Mylan Pulls Health Care Sector Lower
at The Street - Tue Mar 03, 10:28AM CST
Stocks fall back from records on Tuesday morning.
BCS: 16.03 (+0.37), MDR: 3.43 (+0.10), F: 16.03 (-0.14), GE: 25.66 (-0.20), DKS: 55.98 (-0.02), PFE: 34.64 (+0.08), C: 53.67 (-0.06), MYL: 55.60 (+0.16), BBY: 39.79 (+0.61), LL: 35.64 (-5.14), CELG: 119.57 (+1.10), AZO: 652.48 (+0.58), GILD: 103.06 (+0.27), GM: 37.57 (-0.23), LEAF: 49.91 (-0.32)
Glaucoma - Pipeline Review, H1 2015 - Featuring 50 Companies & 104 Drug Profiles
M2 - Tue Mar 03, 5:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/8h3k7s/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AC Immune SA - Acadia Pharmaceuticals Inc. - Aerie Pharmaceuticals, Inc. - Alcon, Inc. - Allergan, Inc. - Altacor Ltd. - Amakem NV - Asahi Kasei Pharma Corp. - AUS Bio Limited - Bausch & Lomb Incorporated - Bionure Farma, S.L. - Can-Fite BioPharma Ltd. - Cellular Biomedicine Group, Inc. - China Grand Wuhan General Pharmaceutical Research Institute - D. Western Therapeutics Institute, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - F. Hoffmann-La Roche Ltd. - Foamix Pharmaceuticals Ltd. - Gene Signal International SA - Gilead Sciences, Inc. - Handok Inc. - High Point Pharmaceuticals, LLC - Icon Bioscience, Inc. - IMMD Inc. - Inotek Pharmaceuticals Corporation - InSite Vision Incorporated - Lacer, S.A. - Merck & Co., Inc. - Merz Pharma GmbH & Co. KgaA For more information visit http://www.researchandmarkets.com/research/8h3k7s/glaucoma
CANF: 4.40 (-0.10), AGN: 235.68 (+0.82), ACAD: 38.14 (unch), ITEK: 6.00 (unch), GILD: 103.06 (+0.27), MRK: 57.88 (-0.46), FOMX: 8.97 (-0.05), AERI: 28.80 (+0.20), CBMG: 29.50 (-0.34)
Non-Alcoholic Steatohepatitis Therapeutics Pipeline Review 2015 - Analysis of 32 Companies & 53 Drug Profiles
M2 - Tue Mar 03, 5:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/np53sj/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cardax Pharmaceuticals, Inc. - Conatus Pharmaceuticals Inc. - Connexios Life Sciences Pvt. Ltd. - Cubist Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Dr. Falk Pharma GmbH - Dynavax Technologies Corporation - Galectin Therapeutics, Inc. - Galmed International Ltd. - Genfit SA - Gilead Sciences, Inc. - Immuron Limited - Intercept Pharmaceuticals, Inc. - Isis Pharmaceuticals, Inc. - Jenrin Discovery, Inc. - Kadmon Corporation, LLC - Kissei Pharmaceutical Co., Ltd. - Kyorin Pharmaceutical Co., Ltd. - La Jolla Pharmaceutical Company - Mochida Pharmaceutical Co., Ltd. - Novo Nordisk A/S - Pharmaxis Limited - Phenex Pharmaceuticals AG - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Shire Plc - Stelic Institute & Co. - Tobira Therapeutics, Inc. - Verva Pharmaceuticals Limited For more information visit http://www.researchandmarkets.com/research/np...nalcoholic
DVAX: 21.30 (+1.58), CBSTZ: 0.06 (unch), CNAT: 6.30 (-0.02), GALT: 3.57 (+0.20), NVO: 47.05 (-0.17), RPTP: 10.30 (+0.69), ISIS: 70.16 (+1.50), GILD: 103.06 (+0.27), SHPG: 239.64 (+0.74), ICPT: 266.49 (+19.13), TBRA: ()
New Investor Dividend Growth Portfolio
The Value Portfolio - at Seeking Alpha - Tue Mar 03, 3:57AM CST
T: 34.00 (-0.41), JNJ: 101.65 (-0.69), GE: 25.66 (-0.20), HCP: 41.78 (-0.44), GILD: 103.06 (+0.27), ESV: 24.00 (-0.14), O: 50.34 (-0.21), RCS: 9.72 (+0.03)
Gilead Sciences to Present at the Cowen and Company 35th Annual Health Care Conference on Tuesday, March 3
Business Wire - Mon Mar 02, 4:00PM CST
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its corporate presentation will be webcast from the Cowen and Company 35th Annual Health Care Conference in Boston.
GILD: 103.06 (+0.27)
Gilead's (GILD) HIV Drug Positive in 2 Phase III Studies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 02, 3:34PM CST
Gilead Sciences, Inc. (GILD) announced detailed results from two phase III studies on investigational HIV therapy containing tenofovir alafenamide.
CYTK: 7.95 (-0.02), ISIS: 70.16 (+1.50), GILD: 103.06 (+0.27), ANIP: 67.18 (+0.32)
Nasdaq 5,000 Is Signaling a 'Broader' Bull Market in Stocks
at The Street - Mon Mar 02, 1:40PM CST
Almost 15 years to the day in which the Nasdaq Composite hit a record high, the index hit the 5,000-mark on Monday -- the first time since its bust.
YHOO: 43.99 (+1.37), GILD: 103.06 (+0.27), FB: 80.89 (+1.29), QCOM: 70.84 (-0.56), AMAT: 24.27 (-0.22), JDSU: 13.19 (-0.32), GOOGL: 578.33 (-0.46), MSFT: 43.06 (-0.22), INTC: 34.12 (+0.02), AAPL: 128.54 (-0.82), ORCL: 43.61 (+0.23), CSCO: 29.33 (-0.21)
Midday Glance: Biotechnology companies
AP - Wed Mar 04, 12:16PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
GILD: 103.06 (+0.27), AMGN: 159.19 (+0.63), CELG: 119.57 (+1.10)
Biotech Stock Roundup: Orexigen Soars on Contrave Data, Amgen Scores in Study - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 04, 10:35AM CST
Orexigen (OREX) soars on news regrading obesity drug, Contrave. Amgen's (AMGN) multiple myeloma drug, Kyprolis, is better than Velcade in a head-to-head study.
OREX: 8.49 (+0.85), VRTX: 120.05 (-3.47), ISIS: 70.16 (+1.50), GILD: 103.06 (+0.27), AMGN: 159.19 (+0.63), ARNA: 4.32 (+0.28), CELG: 119.57 (+1.10)
Early Glance: Biotechnology companies
AP - Wed Mar 04, 9:36AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
GILD: 103.06 (+0.27), AMGN: 159.19 (+0.63), CELG: 119.57 (+1.10)
CVS Health Wins Over Analysts As Significant Growth Expected In The Next 5 Years
Equity Watch - at Seeking Alpha - Wed Mar 04, 8:17AM CST
GILD: 103.06 (+0.27), CVS: 103.08 (-0.37)
Pioneer Fundamental Growth Fund: Why Is It Revving Up?
at Investor's Business Daily - Tue Mar 03, 5:50PM CST
Stock mutual fund managers Andrew Acheson and Paul Cloonan have been kicking it into a higher gear at Pioneer Fundamental Growth Fund. The 16.61% average annual return of their $2.4 billion fund ranked in the top 27% of its large-cap growth rivals...
SBUX: 93.06 (-0.94), ESRX: 84.83 (+0.48), LNKD: 265.23 (-0.31), GILD: 103.06 (+0.27), ABBV: 60.27 (+0.65), AAPL: 128.54 (-0.82), CELG: 119.57 (+1.10)
Final Glance: Biotechnology companies
AP - Tue Mar 03, 5:05PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 103.06 (+0.27), AMGN: 159.19 (+0.63), CELG: 119.57 (+1.10)
Amgen: The Best Biotech Stock You Don't Own
Dan Strack - at Seeking Alpha - Tue Mar 03, 4:04PM CST
BIIB: 414.13 (+1.34), GILD: 103.06 (+0.27), PFE: 34.64 (+0.08), MRK: 57.88 (-0.46), AMGN: 159.19 (+0.63), ABBV: 60.27 (+0.65), GSK: 47.82 (+0.11), BMY: 65.67 (+3.75), HSP: 87.95 (+0.24), NVS: 99.04 (-0.02), CELG: 119.57 (+1.10)
Stock Markets Take a Breather After Monday's Record Run
at The Street - Tue Mar 03, 3:11PM CST
Stocks took a break from smashing records and hitting multi-year highs on Tuesday.
BCS: 16.03 (+0.37), PSX: 77.96 (-0.13), F: 16.03 (-0.14), DKS: 55.98 (-0.02), PFE: 34.64 (+0.08), C: 53.67 (-0.06), MYL: 55.60 (+0.16), BBY: 39.79 (+0.61), COP: 64.25 (-0.53), LL: 35.64 (-5.14), XLV: 72.58 (+0.35), CELG: 119.57 (+1.10), AZO: 652.48 (+0.58), TOT: 52.82 (-0.27), GILD: 103.06 (+0.27), TGT: 77.72 (-0.28), LEAF: 49.91 (-0.32), GM: 37.57 (-0.23), BP: 41.53 (-0.21), XLE: 78.65 (-0.11), BABA: 85.49 (+3.91)
Gilead Sciences' (GILD) Management Presents at Cowen & Company 35th Annual Health Care Conference (Transcript)
SA Transcripts - at Seeking Alpha - Tue Mar 03, 3:03PM CST
GILD: 103.06 (+0.27)
Stocks Recover From Lows After Crude Oil Jumps Over $50
at The Street - Tue Mar 03, 2:22PM CST
Stocks move off session lows by mid-afternoon Tuesday, buoyed by a rally in oil prices.
BCS: 16.03 (+0.37), F: 16.03 (-0.14), GE: 25.66 (-0.20), DKS: 55.98 (-0.02), PFE: 34.64 (+0.08), C: 53.67 (-0.06), MYL: 55.60 (+0.16), BBY: 39.79 (+0.61), LL: 35.64 (-5.14), XLV: 72.58 (+0.35), CELG: 119.57 (+1.10), AZO: 652.48 (+0.58), GILD: 103.06 (+0.27), GM: 37.57 (-0.23), LEAF: 49.91 (-0.32), BABA: 85.49 (+3.91)
Nasdaq Hits 5000: 3 Choices to Ride the Upswing - Analyst Blog
Swarup Gupta - Zacks Investment Research - Tue Mar 03, 10:36AM CST
Echoes of the dot-com boom could be heard yesterday after the Nasdaq closed above 5,000 for the first time in 15 years.
AMZN: 382.72 (-1.89), BIIB: 414.13 (+1.34), FB: 80.89 (+1.29), AMGN: 159.19 (+0.63), H: 60.77 (-0.49), INTC: 34.12 (+0.02), PCLN: 1,225.67 (-16.36), CELG: 119.57 (+1.10), SBUX: 93.06 (-0.94), GILD: 103.06 (+0.27), MSFT: 43.06 (-0.22), AAPL: 128.54 (-0.82), CSCO: 29.33 (-0.21), ONNN: 13.02 (+0.15)
Stocks Slip From Highs; Mylan Pulls Health Care Sector Lower
at The Street - Tue Mar 03, 10:28AM CST
Stocks fall back from records on Tuesday morning.
BCS: 16.03 (+0.37), MDR: 3.43 (+0.10), F: 16.03 (-0.14), GE: 25.66 (-0.20), DKS: 55.98 (-0.02), PFE: 34.64 (+0.08), C: 53.67 (-0.06), MYL: 55.60 (+0.16), BBY: 39.79 (+0.61), LL: 35.64 (-5.14), CELG: 119.57 (+1.10), AZO: 652.48 (+0.58), GILD: 103.06 (+0.27), GM: 37.57 (-0.23), LEAF: 49.91 (-0.32)
Glaucoma - Pipeline Review, H1 2015 - Featuring 50 Companies & 104 Drug Profiles
M2 - Tue Mar 03, 5:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/8h3k7s/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AC Immune SA - Acadia Pharmaceuticals Inc. - Aerie Pharmaceuticals, Inc. - Alcon, Inc. - Allergan, Inc. - Altacor Ltd. - Amakem NV - Asahi Kasei Pharma Corp. - AUS Bio Limited - Bausch & Lomb Incorporated - Bionure Farma, S.L. - Can-Fite BioPharma Ltd. - Cellular Biomedicine Group, Inc. - China Grand Wuhan General Pharmaceutical Research Institute - D. Western Therapeutics Institute, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - F. Hoffmann-La Roche Ltd. - Foamix Pharmaceuticals Ltd. - Gene Signal International SA - Gilead Sciences, Inc. - Handok Inc. - High Point Pharmaceuticals, LLC - Icon Bioscience, Inc. - IMMD Inc. - Inotek Pharmaceuticals Corporation - InSite Vision Incorporated - Lacer, S.A. - Merck & Co., Inc. - Merz Pharma GmbH & Co. KgaA For more information visit http://www.researchandmarkets.com/research/8h3k7s/glaucoma
CANF: 4.40 (-0.10), AGN: 235.68 (+0.82), ACAD: 38.14 (unch), ITEK: 6.00 (unch), GILD: 103.06 (+0.27), MRK: 57.88 (-0.46), FOMX: 8.97 (-0.05), AERI: 28.80 (+0.20), CBMG: 29.50 (-0.34)
Non-Alcoholic Steatohepatitis Therapeutics Pipeline Review 2015 - Analysis of 32 Companies & 53 Drug Profiles
M2 - Tue Mar 03, 5:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/np53sj/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cardax Pharmaceuticals, Inc. - Conatus Pharmaceuticals Inc. - Connexios Life Sciences Pvt. Ltd. - Cubist Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Dr. Falk Pharma GmbH - Dynavax Technologies Corporation - Galectin Therapeutics, Inc. - Galmed International Ltd. - Genfit SA - Gilead Sciences, Inc. - Immuron Limited - Intercept Pharmaceuticals, Inc. - Isis Pharmaceuticals, Inc. - Jenrin Discovery, Inc. - Kadmon Corporation, LLC - Kissei Pharmaceutical Co., Ltd. - Kyorin Pharmaceutical Co., Ltd. - La Jolla Pharmaceutical Company - Mochida Pharmaceutical Co., Ltd. - Novo Nordisk A/S - Pharmaxis Limited - Phenex Pharmaceuticals AG - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Shire Plc - Stelic Institute & Co. - Tobira Therapeutics, Inc. - Verva Pharmaceuticals Limited For more information visit http://www.researchandmarkets.com/research/np...nalcoholic
DVAX: 21.30 (+1.58), CBSTZ: 0.06 (unch), CNAT: 6.30 (-0.02), GALT: 3.57 (+0.20), NVO: 47.05 (-0.17), RPTP: 10.30 (+0.69), ISIS: 70.16 (+1.50), GILD: 103.06 (+0.27), SHPG: 239.64 (+0.74), ICPT: 266.49 (+19.13), TBRA: ()
New Investor Dividend Growth Portfolio
The Value Portfolio - at Seeking Alpha - Tue Mar 03, 3:57AM CST
T: 34.00 (-0.41), JNJ: 101.65 (-0.69), GE: 25.66 (-0.20), HCP: 41.78 (-0.44), GILD: 103.06 (+0.27), ESV: 24.00 (-0.14), O: 50.34 (-0.21), RCS: 9.72 (+0.03)
Gilead Sciences to Present at the Cowen and Company 35th Annual Health Care Conference on Tuesday, March 3
Business Wire - Mon Mar 02, 4:00PM CST
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its corporate presentation will be webcast from the Cowen and Company 35th Annual Health Care Conference in Boston.
GILD: 103.06 (+0.27)
Gilead's (GILD) HIV Drug Positive in 2 Phase III Studies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 02, 3:34PM CST
Gilead Sciences, Inc. (GILD) announced detailed results from two phase III studies on investigational HIV therapy containing tenofovir alafenamide.
CYTK: 7.95 (-0.02), ISIS: 70.16 (+1.50), GILD: 103.06 (+0.27), ANIP: 67.18 (+0.32)
Nasdaq 5,000 Is Signaling a 'Broader' Bull Market in Stocks
at The Street - Mon Mar 02, 1:40PM CST
Almost 15 years to the day in which the Nasdaq Composite hit a record high, the index hit the 5,000-mark on Monday -- the first time since its bust.
YHOO: 43.99 (+1.37), GILD: 103.06 (+0.27), FB: 80.89 (+1.29), QCOM: 70.84 (-0.56), AMAT: 24.27 (-0.22), JDSU: 13.19 (-0.32), GOOGL: 578.33 (-0.46), MSFT: 43.06 (-0.22), INTC: 34.12 (+0.02), AAPL: 128.54 (-0.82), ORCL: 43.61 (+0.23), CSCO: 29.33 (-0.21)
(0)
(0)